Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marit J van Gils

Showing results (21-30 of 222) with videos related to

Pageof 23
Sort By:
Journal of Virology|January 15, 2010
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressorsMarit J van Gils, Evelien M Bunnik, Judith A Burger, et al.
Journal of Virology|January 28, 2021
Production of HIV-1 Env-specific antibodies mediating innate immune functions depends on cognate IL-21- secreting CD4+ T cellsJernej Pušnik, Stephanie Fischinger, Ulf Dittmer, et al.
Virology|June 23, 2009
Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infectionEvelien M Bunnik, Marit J van Gils, Marilie S D Lobbrecht, et al.
Journal of Virology|June 10, 2011
Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serumMarit J van Gils, Diana Edo-Matas, Emma J Bowles, et al.
Frontiers in Nutrition|July 18, 2022
Maternal Stress and Human Milk Antibodies During the COVID-19 PandemicHannah G Juncker, Eliza J M Ruhé, Aniko Korosi, et al.
Journal of Virology|May 20, 2011
Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodiesMarit J van Gils, Evelien M Bunnik, Brigitte D Boeser-Nunnink, et al.
Plos One|September 17, 2013
HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humansDelphine C Malherbe, Rogier W Sanders, Marit J van Gils, et al.
AIDS (London, England)|February 22, 2014
Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizersTom L G M van den Kerkhof, Zelda Euler, Marit J van Gils, et al.
JAMA Pediatrics|March 14, 2022
Comparing Human Milk Antibody Response After 4 Different Vaccines for COVID-19Hannah G Juncker, Sien J Mulleners, Esmée R M Coenen, et al.
AIDS (London, England)|June 4, 2016
Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodiesTom L G M van den Kerkhof, Marit J van Gils, Brigitte D Boeser-Nunnink, et al.
Pageof 23

Showing results (21-30 of 222) with videos related to

Sort By:
Pageof 23
Journal of Virology|January 15, 2010
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressorsMarit J van Gils, Evelien M Bunnik, Judith A Burger, et al.
Journal of Virology|January 28, 2021
Production of HIV-1 Env-specific antibodies mediating innate immune functions depends on cognate IL-21- secreting CD4+ T cellsJernej Pušnik, Stephanie Fischinger, Ulf Dittmer, et al.
Virology|June 23, 2009
Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infectionEvelien M Bunnik, Marit J van Gils, Marilie S D Lobbrecht, et al.
Journal of Virology|June 10, 2011
Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serumMarit J van Gils, Diana Edo-Matas, Emma J Bowles, et al.
Frontiers in Nutrition|July 18, 2022
Maternal Stress and Human Milk Antibodies During the COVID-19 PandemicHannah G Juncker, Eliza J M Ruhé, Aniko Korosi, et al.
Journal of Virology|May 20, 2011
Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodiesMarit J van Gils, Evelien M Bunnik, Brigitte D Boeser-Nunnink, et al.
Plos One|September 17, 2013
HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humansDelphine C Malherbe, Rogier W Sanders, Marit J van Gils, et al.
AIDS (London, England)|February 22, 2014
Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizersTom L G M van den Kerkhof, Zelda Euler, Marit J van Gils, et al.
JAMA Pediatrics|March 14, 2022
Comparing Human Milk Antibody Response After 4 Different Vaccines for COVID-19Hannah G Juncker, Sien J Mulleners, Esmée R M Coenen, et al.
AIDS (London, England)|June 4, 2016
Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodiesTom L G M van den Kerkhof, Marit J van Gils, Brigitte D Boeser-Nunnink, et al.
Pageof 23